Supernus Pharmaceuticals Net Profit Margin 2011-2024 | SUPN
Supernus Pharmaceuticals net profit margin from 2011 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Supernus Pharmaceuticals Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-09-30 |
$0.65B |
$0.06B |
9.05% |
| 2024-06-30 |
$0.63B |
$0.01B |
0.79% |
| 2024-03-31 |
$0.60B |
$-0.02B |
-2.68% |
| 2023-12-31 |
$0.61B |
$0.00B |
0.16% |
| 2023-09-30 |
$0.61B |
$0.03B |
4.09% |
| 2023-06-30 |
$0.63B |
$0.04B |
6.78% |
| 2023-03-31 |
$0.67B |
$0.05B |
7.78% |
| 2022-12-31 |
$0.67B |
$0.06B |
9.15% |
| 2022-09-30 |
$0.66B |
$0.04B |
5.77% |
| 2022-06-30 |
$0.63B |
$0.06B |
9.21% |
| 2022-03-31 |
$0.60B |
$0.07B |
12.31% |
| 2021-12-31 |
$0.58B |
$0.05B |
9.33% |
| 2021-09-30 |
$0.56B |
$0.08B |
14.72% |
| 2021-06-30 |
$0.57B |
$0.10B |
17.69% |
| 2021-03-31 |
$0.56B |
$0.11B |
20.11% |
| 2020-12-31 |
$0.52B |
$0.13B |
24.57% |
| 2020-09-30 |
$0.48B |
$0.13B |
27.25% |
| 2020-06-30 |
$0.42B |
$0.12B |
28.07% |
| 2020-03-31 |
$0.40B |
$0.12B |
29.10% |
| 2019-12-31 |
$0.39B |
$0.11B |
28.83% |
| 2019-09-30 |
$0.41B |
$0.11B |
25.98% |
| 2019-06-30 |
$0.41B |
$0.11B |
25.67% |
| 2019-03-31 |
$0.40B |
$0.10B |
25.50% |
| 2018-12-31 |
$0.41B |
$0.11B |
27.14% |
| 2018-09-30 |
$0.38B |
$0.10B |
25.98% |
| 2018-06-30 |
$0.36B |
$0.09B |
24.30% |
| 2018-03-31 |
$0.33B |
$0.07B |
21.86% |
| 2017-12-31 |
$0.30B |
$0.06B |
18.87% |
| 2017-09-30 |
$0.28B |
$0.06B |
20.65% |
| 2017-06-30 |
$0.25B |
$0.10B |
40.71% |
| 2017-03-31 |
$0.23B |
$0.10B |
41.92% |
| 2016-12-31 |
$0.22B |
$0.09B |
42.33% |
| 2016-09-30 |
$0.20B |
$0.08B |
42.64% |
| 2016-06-30 |
$0.18B |
$0.03B |
14.53% |
| 2016-03-31 |
$0.16B |
$0.02B |
11.04% |
| 2015-12-31 |
$0.15B |
$0.01B |
9.46% |
| 2015-09-30 |
$0.14B |
$0.01B |
8.15% |
| 2015-06-30 |
$0.12B |
$0.01B |
4.20% |
| 2015-03-31 |
$0.11B |
$0.01B |
5.31% |
| 2014-12-31 |
$0.09B |
$-0.01B |
-11.83% |
| 2014-09-30 |
$0.07B |
$-0.04B |
-51.39% |
| 2014-06-30 |
$0.05B |
$-0.06B |
-118.00% |
| 2014-03-31 |
$0.02B |
$-0.09B |
-445.00% |
| 2013-12-31 |
$0.01B |
$-0.09B |
-827.27% |
| 2013-09-30 |
$0.00B |
$-0.08B |
-4150.00% |
| 2013-06-30 |
$0.00B |
$-0.07B |
-7200.00% |
| 2013-03-31 |
$0.00B |
$-0.06B |
-5500.00% |
| 2012-12-31 |
$0.00B |
$-0.05B |
-4700.00% |
| 2012-09-30 |
$0.00B |
$0.05B |
inf% |
| 2012-06-30 |
$0.00B |
$0.05B |
inf% |
| 2012-03-31 |
$0.00B |
$0.05B |
5300.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
